CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Pretoria Gauteng, South Africa

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

    Phase

    2/3

    Span

    198 weeks

    Sponsor

    Gilead Sciences

    Pretoria

    Recruiting

  • Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Phase

    3

    Span

    189 weeks

    Sponsor

    AbbVie

    Pretoria, Gauteng

    Recruiting

  • Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

    Phase

    3

    Span

    128 weeks

    Sponsor

    Arrowhead Pharmaceuticals

    Pretoria, Gauteng

    Recruiting

  • Study of Plozasiran in Adults With Severe Hypertriglyceridemia

    Phase

    3

    Span

    119 weeks

    Sponsor

    Arrowhead Pharmaceuticals

    Pretoria, Gauteng

    Recruiting

  • A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa

    Phase

    3

    Span

    131 weeks

    Sponsor

    AbbVie

    Pretoria, Gauteng

    Recruiting

  • A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

    This is a global, multicenter, randomized, double-blind, parallel group, placebo-controlled phase 3 study investigating the efficacy, safety and tolerability of barzolvolimab in adult participants with Chronic Spontaneous Urticaria (CSU) who are symptomatic despite treatment with non-sedating second generation H1-antihistamines at 1-4 times the locally approved dose. There is a screening period of up to 4 weeks, followed by a 24-week placebo-controlled treatment period, a 28-week active treatment period where all participants receive barzolvolimab followed by a 16-week treatment free period. Approximately 915 adult participants (610 in the active arms and 305 in the placebo arm) will be randomly assigned to the treatment arms.

    Phase

    3

    Span

    147 weeks

    Sponsor

    Celldex Therapeutics

    Pretoria, Gauteng

    Recruiting

  • Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

    The purpose of this study is to investigate the effect of balcinrenone/dapagliflozin compared with dapagliflozin, on the risk of CV death, HF event with and without hospitalisation, in patients with chronic HF, impaired kidney function, and who have had a recent HF event. Eligible patients will randomly be assigned with a 1:1:1 ratio to receive once daily administration of one capsule and one tablet of one of the following treatments: 1. Balcinrenone/dapagliflozin 15 mg/10 mg capsule and matching placebo for dapagliflozin 10 mg tablet 2. Balcinrenone/dapagliflozin 40 mg/10 mg capsule and matching placebo for dapagliflozin 10 mg tablet 3. Dapagliflozin 10 mg tablet and matching placebo for balcinrenone/dapagliflozin capsule The study is event driven, and the average study duration for a participant is estimated to be 22 months including screening period, 20 months blinded treatment period and a one-month follow-up period on open-label dapagliflozin. The study will be conducted at approximately 700 sites in approximately 40 countries globally.

    Phase

    3

    Span

    165 weeks

    Sponsor

    AstraZeneca

    Pretoria

    Recruiting

  • A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments

    Phase

    4

    Span

    501 weeks

    Sponsor

    Gilead Sciences

    Pretoria

    Recruiting

  • Study for Subjects with Relapsed/Refractory Non-Hodgkin Lymphoma

    This is a phase 1, first-in-human (FIH), open-label study to evaluate the safety of CD19 t-haNK as a single agent and the safety and preliminary efficacy of CD19 t haNK in combination with rituximab in subjects with selected CD19+ and CD20+ R/R B-cell non-Hodgkin lymphoma (NHL). Up to 10 subjects will receive at least 1 dose of study drug. The initial 3 subjects will receive study drug in a staggered fashion, with a 7 day interval between each subject to evaluate any toxicities. Subjects will initially receive a single 3 week cycle of the CD19 t haNK as a single-agent regimen. Following a 1-week safety pause, subjects will then receive a 3 week cycle of CD19 t-haNK in combination with rituximab. Subjects will then undergo the first tumor assessment. Subjects with no evidence of progressive disease (PD) will be eligible to receive up to 2 additional 3 week cycles of CD19 t haNK in combination with rituximab.

    Phase

    1

    Span

    136 weeks

    Sponsor

    ImmunityBio, Inc.

    Pretoria, Gauteng

    Recruiting

  • A Simple Intervention to Increase Persistence on PrEP in MSM to Improve Decision Making

    Phase

    N/A

    Span

    75 weeks

    Sponsor

    Boston University

    Pretoria, Gauteng

    Recruiting

1-10 of 90
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 703.538.7600
Toll Free: 888.838.5578

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information